Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Feb;70(2):247-251.
doi: 10.1097/MPG.0000000000002575.

Severe Abdominal Manifestations in Juvenile Dermatomyositis

Caroline Besnard  1 , Cyril Gitiaux  2   3 , Muriel Girard  2   4   5   6 , Louise Galmiche-Rolland  7 , Cécile Talbotec  4 , Pierre Quartier  1   2   8 , Christine Bodemer  2   9 , Laureline Berteloot  10 , Brigitte Bader-Meunier  1   8
Affiliations
Observational Study

Severe Abdominal Manifestations in Juvenile Dermatomyositis

Caroline Besnard et al. J Pediatr Gastroenterol Nutr. 2020 Feb.

Abstract

Juvenile dermatomyositis (JDM) is a rare and heterogeneous pediatric-onset idiopathic inflammatory myopathy. Gastrointestinal (GI) involvement occurs in 22% to 37% of JDM patients but has only been described in case reports. In this retrospective, single-center, observational study, we aimed to assess the causes and management of severe GI manifestations in JDM patients. We studied a cohort of 9 patients among 110 JDM patients followed during the study period (8.3%). The GI complications were related to JDM in most cases (17/19), with digestive tract involvement (n = 10), acute pancreatitis (n = 4), and hepatitis (n = 3). Three patients died from refractory JDM 2.9 years (2-3.6) after the JDM diagnosis. We highlight the need to consider pancreatitis as a main diagnostic factor in JDM patients with severe GI manifestations and the requirement of early aggressive treatment for these patients.

PubMed Disclaimer

References

    1. Feldman BM, Rider LG, Reed AM, et al. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. The Lancet 2008; 371:2201–2212.
    1. Besançon A, Brochard K, Dupic L, et al. Presentations and outcomes of juvenile dermatomyositis patients admitted to intensive care units. Rheumatology 2017; 56:1814–1816.
    1. Robinson AB, Hoeltzel MF, Wahezi DM, et al. Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry: Investigating Juvenile DM Through a National Multicenter Registry. Arthritis Care Res 2014; 66:404–410.
    1. Brown VE, Pilkington CA, Feldman BM, et al. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology 2006; 45:990–993.
    1. Aouizerate J, De Antonio M, Bader-Meunier B, et al. Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis. Rheumatology (Oxford) 2018; 57:873–887.

Publication types